In the CDDP treatment group, Bcl-2 protein expression significantly (p < 0.05) decreased by 43% compared with the tumor group, but this increase was not significant (p > 0.05) when compared with the RTP-H treatment group. The gene discussed is BCL2; the disease is neoplasm.